Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

v3.22.4
Earnings Per Share
6 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Earnings Per Share

Note 9. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

    

Quarter Ended

Six Months Ended

December 31, 

December 31, 

    

2022

    

2021

2022

    

2021

Earnings per share – basic:

Net earnings, including noncontrolling interest

$

50,005

 

$

72,059

$

139,739

 

$

141,040

Less net earnings (loss) attributable to noncontrolling interest

-

 

(8,114)

179

 

(8,748)

Net earnings attributable to Bio-Techne

$

50,005

$

80,173

$

139,560

$

149,788

Income allocated to participating securities

 

(10)

 

(34)

 

(35)

 

(70)

Income available to common shareholders

$

49,995

$

80,139

$

139,525

$

149,718

Weighted-average shares outstanding – basic

 

157,011

 

157,240

 

156,887

 

156,808

Earnings per share – basic

$

0.32

$

0.51

$

0.89

$

0.95

Earnings per share – diluted:

 

  

 

  

 

  

 

  

Net earnings, including noncontrolling interest

$

50,005

$

72,059

$

139,739

$

141,040

Less net earnings (loss) attributable to noncontrolling interest

(8,114)

179

(8,748)

Net earnings attributable to Bio-Techne

$

50,005

$

80,173

$

139,560

$

149,788

Income allocated to participating securities

 

(10)

 

(34)

 

(35)

 

(70)

Income available to common shareholders

$

49,995

$

80,139

$

139,525

$

149,718

Weighted-average shares outstanding – basic

 

157,011

 

157,240

 

156,887

 

156,808

Dilutive effect of stock options and restricted stock units

 

4,739

 

7,588

 

4,879

 

7,828

Weighted-average common shares outstanding – diluted

 

161,750

 

164,828

 

161,766

 

164,636

Earnings per share – diluted

$

0.31

$

0.49

$

0.86

$

0.91

The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 4.6 million and 2.8 million for the quarter ended December 31, 2022 and 2021, respectively and 4.6 million and 1.9 million for the six months ended December 31, 2022 and 2021 respectively.